Transaction overview
On March 5, 2026, Jennifer Fitzpatrick, Chief Legal Officer of Sionna Therapeutics, Inc. (NASDAQ:SION), executed the sale of 10,250 shares of common stock for total proceeds of $347,018. The shares were sold at prices that ranged from $32.56 to $34.83 per share.
On the same date Fitzpatrick also exercised options to acquire 10,250 shares of Sionna Therapeutics common stock at an exercise price of $6.11 per share, for a total value of $62,627. These actions were carried out automatically pursuant to a Rule 10b5-1 trading plan that Fitzpatrick adopted on June 5, 2025. Following the transactions, Fitzpatrick's direct ownership of common stock is reported as zero shares.
Share-price backdrop
Since those transactions the Sionna Therapeutics share price has moved higher to $36. That level reflects a 121% gain over the past year and a 50% increase over the last six months.
Analyst coverage and company cash position
Several analyst actions and company disclosures were highlighted alongside the insider activity. Guggenheim has raised its price target on Sionna to $50 while retaining a Buy rating. Raymond James increased its price target to $53, citing potential value from upcoming proof-of-concept readouts for the NBD1 stabilizers SION-719 and SION-451, which are expected around mid-2026. Citizens initiated coverage with a Market Outperform rating and a $63 price target derived from a risk-adjusted discounted cash flow model.
The company reported ending fiscal year 2025 with $310.3 million in cash and has provided guidance that its cash runway extends until 2028.
Valuation signal from InvestingPro
InvestingPro analysis included in the reporting indicates that, on its Fair Value assessment, Sionna Therapeutics currently appears overvalued. The platform also notes that subscribers can access additional ProTips and financial metrics for deeper analysis.
Context and takeaway
The record of the transactions, the timing under a Rule 10b5-1 plan, the simultaneous exercise of options, the company's cash position, and the set of recent analyst updates are all presented as factual elements surrounding the insider action. The combination of a substantial insider sale executed automatically, concurrent option exercises, robust recent share gains, and divergent valuation signals provides a compact factual snapshot for investors evaluating Sionna Therapeutics.